Stand Up To Cancer Hails FDA Approval of Encorafenib + Cetuximab Combination for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer - Stand Up To Cancer


Posted April 29, 2020

Stand Up To Cancer Hails FDA Approval of Encorafenib + Cetuximab Combination for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

Stand Up To Cancer-Dutch Cancer Society Research Team Focused on DNA-Guided Personalized Cancer Treatment Contributed to Approval

Ruling is the 7th FDA Approval Supported by SU2C Research

(New York) April 29, 2020 – Stand Up To Cancer (SU2C) welcomed the recent Food and Drug Administration (FDA) approval this month of encorafenib in combination with cetuximab for patients with advanced BRAF-mutated colorectal cancer. Research by the SU2C-Dutch Cancer Society (KWF) Translational Research Team: Prospective Use of DNA-Guided Personalized Cancer Treatment contributed to the development of this treatment.

“This is the seventh FDA approval for a new cancer therapy supported by SU2C research,” said Nobel Laureate Phillip A. Sharp, PhD, chair of the SU2C Scientific Advisory Committee, and Institute professor, David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology. “The work of this team demonstrates how SU2C’s research accelerates development of new effective treatments showing promise in patients.”

BRAF-mutant colorectal cancer is a hard to treat type of colorectal cancer that affects 10 to 15 percent of colorectal patients. Across the US and Canada, approximately, this new treatment could potentially help between 17,500-26,000 patients each year.

“Colorectal cancer is the second leading cause of cancer death in men and women combined,” stated SU2C CEO Sung Poblete, PhD, RN. “Stand Up To Cancer is proud to have contributed to the development of this new targeted treatment option for people with the historically difficult to treat colorectal cancer whose cancer has progressed, despite receiving prior therapy.”

The SU2C-KWF Research Team participated in a Phase 1b/ Phase 2 multi-institutional dose escalation clinical trial (NCT01719380) which studied the effects of encorafenib, alpelisib and cetuximab in BRAF-mutated colorectal cancers. The study compared a two-drug combination of encorafenib and cetuximab; and a triple-drug combination of encorafenib, alpelisib, and cetuximab. Both combinations showed promise for treating metastatic colorectal cancer characterized by BFAF mutations and were well tolerated by the patients. The team made an important observation that patients carrying key mutations in genes associated with the MAP kinase signaling pathway were more responsive to the combination.

Supported by the team’s findings, the FDA granted Breakthrough Therapy Designations for both the combination of encorafenib, binimetinib, and cetuximab and the combination of encorafenib and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer, which sped regulatory review.

“We now have clinical proof that science can guide smart treatment combinations which will further stimulate intelligent use of combinations of targeted anti-cancer drugs,” said Emile Voest, MD, PhD, professor of Medical Oncology, medical director of the Netherlands Cancer Institute, and leader of the SU2C-KWF Translational Research Team: Prospective Use of DNA-Guided Personalized Cancer Treatment.

“These results highlight how novel insights gained from basic research can lead to novel therapeutic options for cancer patients,” said Rene Bernards, PhD, Netherlands Cancer Institute, and co-leader of the Research Team.

This Research Team engaged just over a dozen scientists from the Netherlands Cancer Institute, Erasmus Medical Center, University Medical Center Utrecht in the Netherlands, and University of California San Diego and UC San Francisco.

About Stand Up To Cancer
Stand Up To Cancer® (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a division of the Entertainment Industry Foundation, a 501(c)(3) charitable organization, was established in 2008 by media and entertainment leaders who utilize these communities’ resources to engage the public in supporting a new, collaborative model of cancer research, to increase awareness about cancer prevention, and to highlight progress being made in the fight against the disease. As of January 2020, more than 1,600 scientists representing more than 180 institutions are involved in SU2C-funded research projects.

Under the direction of our Scientific Advisory Committee, led by Nobel laureate Phillip A. Sharp, Ph.D., SU2C operates rigorous competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and ensure collaboration across research programs.

Current members of the SU2C Council of Founders and Advisors (CFA) include Katie Couric, Sherry Lansing, Kathleen Lobb, Lisa Paulsen, Rusty Robertson, Sue Schwartz, Pamela Oas Williams, and Ellen Ziffren. The late Laura Ziskin and the late Noreen Fraser are also co-founders. Sung Poblete, Ph.D., R.N., serves as SU2C’s CEO. For more information, visit

# # #

Stand Up To Cancer Media Contacts:
Jane E. Rubinstein
Sr VP Communications
516-993-0708 cell

Mirabai Vogt-James
VP Communications
310-739-5576 cell


Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Please validate the captcha
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.